B

Biocytogen

Antibody discovery and preclinical CRO services

Business Development Manager - Product & Services

Full-TimeUpdated on 10/17/2026
$100k - $110k
Expert
PhD
New York, NY, USA
Remote
Sales & Account ManagementAccount Executive

About the job

Requirements
  • A Ph.D. in the bioscience field is required.
  • A strong interest in learning advances in biopharmaceutical science and business is required.
  • The candidate must enjoy networking with leading scientists from biotechnology and biopharmaceutical companies.
  • Excellent written and oral communication skills are required.
  • The candidate must be willing to travel for customer meetings and conferences or vendor shows.
Responsibilities
  • Master the science and business skills in the fields described, including immuno-oncology, animal model gene engineering, and preclinical pharmacology.
  • Actively reach out to prospective customers, explore business opportunities, manage negotiations, and secure contracts.
  • Attend trade shows and relevant conferences.
  • Support the Marketing Team in branding and building marketplace awareness.
Desired Qualifications
  • A proven track record of revenue generation is a plus.

About the company

B

Biocytogen

View
Website

Biocytogen provides integrated solutions for antibody drug research and development through two main lines: BioMice, a preclinical CRO offering custom gene editing, humanized mouse models, and in vivo pharmacology; and antibody discovery for licensing and partnerships. Its RenMice platforms (RenMab, RenLite, RenNano) generate fully human antibodies using Size-Unlimited and Precise Chromosome Engineering, enabling diverse, high-affinity antibodies. It backs discovery with a large off-the-shelf antibody library via Project Integrum, targeting more than 1,000 antigens and offering licensing and co-development paths. The company stands out by delivering an end-to-end pipeline—from engineered models to antibody platforms and a broad discovery program—designed to shorten clients’ drug development timelines.

Company Size

201-500

Company Stage

IPO

Headquarters

Daxing District, China

Founded

2009

Get referred to Biocytogen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • First-half 2026 revenue reached RMB 941 million, up 51.6%, with RMB 241 million profit.
  • September 2, 2026 Qilu licensing and July 7 Whitehawk collaboration expanded near-term partnering revenue.
  • June 29, 2026 court victory over Harbour strengthened RenNano freedom-to-operate and partner confidence.

What critics are saying

  • Harbour BioMed’s appeal against the June 29, 2026 RenNano ruling prolongs legal overhang.
  • BCG041 and most partnered assets remain preclinical, keeping value dependent on future external validation.
  • Qilu, Whitehawk, and Sihuan control downstream development, capping Biocytogen’s economics if partners stall.

What makes Biocytogen unique

  • RenMice powers fully human antibodies and few companies match its scale.
  • RenSuper launched May 2026, pairing AI screening with automated validation and manufacturing.
  • Biocytogen disclosed 350-plus global antibody deals by December 2025, proving repeatable platform monetization.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

0%

2 year growth

1%
The Montreal Gazette
Sep 2nd, 2026
Biocytogen enters into non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody to support innovative drug development in neuroscience.

Biocytogen enters into non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody to support innovative drug development in neuroscience. BEIJING - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. ("Qilu Pharmaceutical") for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to...

Pharmaceutical Business Review
Jul 8th, 2026
Biocytogen and Whitehawk partner to develop ADCs.

Biocytogen and Whitehawk partner to develop ADCs. Recommended companies. Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership. Under this collaboration, Biocytogen will offer access to up to five bispecific antibodies via its RenLite platform. Whitehawk Therapeutics will assess them in conjunction with its own ADC linker-payload platform. Following the evaluation, Whitehawk can choose to further advance any resulting BsADC candidates as part of its pipeline. Biocytogen's RenLite platform uses a common light-chain design to support the discovery and optimisation of fully human bispecific antibodies across a wide range of target combinations. This approach is intended to minimise the risk of light-chain mispairing during development and to support subsequent work on BsADCs. The collaboration is structured to leverage Biocytogen's antibody generation capabilities and Whitehawk's expertise in ADC technologies, with the aim of identifying BsADCs that have differentiated targeting characteristics. Biocytogen president and CEO Dr Yuelei Shen said: "Whitehawk has established strong expertise in ADC technology and oncology drug development. This collaboration further expands the application of Biocytogen's fully human bispecific antibodies in ADC development. "We look forward to supporting the efficient advancement of multiple programmes by contributing high-quality antibody molecules and integrated research capabilities to identify differentiated therapeutic candidates and ultimately bringing new treatment options to patients with cancer." Financial terms include an upfront payment to Biocytogen, with eligibility for additional payments tied to development, regulatory and commercial milestones, as well as low single-digit royalties on net sales. Other financial details have not been disclosed. If Whitehawk opts to move forward with any BsADC candidates developed through the partnership, it will hold global rights and complete programme control over them. In April 2026, Biocytogen entered a strategic partnership with Sihuan Pharmaceutical to advance new therapeutics across several disease areas, including weight loss. Related whitepaper. Oxygen Sensor InPro 6860iHD Enter your email address so we can get in touch.

Resonate Group Incorporated
Jul 7th, 2026
Whitehawk swoops in for five ADCs via development deal with China's Biocytogen.

Whitehawk swoops in for five ADCs via development deal with China's Biocytogen. * July 7, 2026 Biocytogen and Whitehawk Therapeutics are joining forces to develop bispecific antibody-drug conjugates using Biocytogen's discovery platform.

Biocytogen
Jun 26th, 2026
Biocytogen recognized in the first tier of the 2026 Top 100 Most Innovative Chinese Pharmaceutical Companies.

Biocytogen recognized in the first tier of the 2026 Top 100 Most Innovative Chinese Pharmaceutical Companies. June 26, 2026 Biocytogen has been recognized in the first tier of the 2026 Top 100 Most Innovative Chinese Pharmaceutical Companies (CPIE 100), announced at the 2026 China Pharmaceutical Innovation Top 100 Conference, held June 26-27 in Tianjin, China. The recognition reflects the company's continued innovation in antibody discovery, proprietary technology platforms, intellectual property, and its expanding portfolio of innovative antibody assets. The China Pharmaceutical Innovation Top 100 is one of China's leading benchmarks for pharmaceutical innovation. The ranking evaluates companies across three dimensions - innovation foundation, innovation process, and innovation outcomes - using four key indicators: core patents for innovative drugs, peripheral patents for innovative drugs, clinical trial activity, and innovative drug approvals and commercialization. Biocytogen's first-tier recognition highlights the company's continued progress in advancing proprietary technologies into differentiated antibody assets with global partnership potential. As of the end of 2025, Biocytogen held 206 granted patents and had filed 475 patent applications across 25 countries and regions. Its proprietary RenMice(R) platform and related core technologies have been granted 29 patents worldwide, with 57 patent applications filed, providing a strong intellectual property foundation for continued innovation and global commercialization. In May 2026, Biocytogen introduced RenSuper(TM) Workstation, its next-generation AI-powered antibody discovery platform. Combining the company's proprietary RenMice(R) platform, an AI-driven antibody analysis engine, and a fully automated antibody production center, RenSuper Workstation offers off-the-shelf access to experimentally validated fully human antibodies against more than 1,000 therapeutic targets. Designed as a one-click therapeutic antibody discovery system, the platform transforms antibody discovery from a project-based workflow into a searchable, programmable, and scalable system. Looking ahead, Biocytogen will continue advancing innovation across its antibody discovery platforms and expanding global collaborations as it pursues its vision of becoming the "Global Headstream of New Drugs". About Biocytogen Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development. Biocytogen has independently developed its proprietary RenMice(R)(RenMab(R)/RenLite(R)/RenNano(R)/RenTCR(TM)/RenTCR mimic(TM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper(TM) Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets - spanning co-development, out-licensing, and transfers - have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice(TM), along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com. Biocytogen Contacts Antibody assets and platforms: [email protected] Media: [email protected]

The Montreal Gazette
Jun 15th, 2026
Biocytogen earns Full AAALAC accreditation, reinforcing excellence in translational research and drug discovery.

Biocytogen earns Full AAALAC accreditation, reinforcing excellence in translational research and drug discovery. BOSTON - Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory animal care and use. The accreditation reflects Biocytogen's continued commitment to maintaining the highest standards of animal welfare, scientific integrity, and operational excellence across its preclinical research...